Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient

2018 ◽  
Vol 38 (10) ◽  
pp. 983-987 ◽  
Author(s):  
Giulio Metro ◽  
Sara Baglivo ◽  
Annamaria Siggillino ◽  
Vienna Ludovini ◽  
Rita Chiari ◽  
...  
Lung Cancer ◽  
2016 ◽  
Vol 91 ◽  
pp. 73-74 ◽  
Author(s):  
Audrey Vallée ◽  
Clarisse Audigier-Valette ◽  
Guillaume Herbreteau ◽  
Julien Merrien ◽  
Laurent Tessonnier ◽  
...  

2019 ◽  
Vol 71 ◽  
pp. 49-51
Author(s):  
Dinesh Chandra Doval ◽  
Rupal Tripathi ◽  
Kumardeep Dutta Choudhury ◽  
Ajay Sharma ◽  
Ullas Batra ◽  
...  

Lung cancer treatment based on the molecular classifi cation of the tumor has paved the way for multiple lines of targeted treatment, even though the development of resistance remains a major cause of concern. Epidermal growth factor receptor (EGFR) remains the poster boy for the use of targeted therapy, and the presence/absence of mutations in this gene has led to the development of inhibitors targeting specifi c mutations. We present the case of an advanced non-small cell lung cancer patient with EGFR T790M mutation treated with Osimertinib, a third-generation inhibitor.


2021 ◽  
Author(s):  
Shunichi Saito ◽  
Gouji Toyokawa ◽  
Seiya Momosaki ◽  
Yuka Kozuma ◽  
Fumihiro Shoji ◽  
...  

2019 ◽  
Vol 58 (3) ◽  
pp. 415-418 ◽  
Author(s):  
Shinichi Morita ◽  
Takeshi Suda ◽  
Chiyumi Oda ◽  
Masaaki Kobayashi ◽  
Takahiro Hoshi ◽  
...  

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yungu Chen ◽  
Yiu Sing Tsang ◽  
Xiaoxia Chou ◽  
Jiong Hu ◽  
Qing Xia

Sign in / Sign up

Export Citation Format

Share Document